



Synthetic Biology in Genomics: Redefining Genetic Engineering and Its Applications in Personalized Medicine

Negin Ehyaei Rad ^{1,*}

¹Department of Pharmacology and Toxicology, School of Pharmacy, University of Medical Sciences, Ardabil, Iran.

Corresponding Author's E-mail: neginrad6478@gmail.com

Abstract:

Synthetic biology, an emerging interdisciplinary field combining biology, engineering, and genomics, has led to transformative advances in genetic engineering. By enabling the design of novel biological systems and organisms, synthetic biology is revolutionizing personalized medicine. This paper examines how synthetic biology intersects with genomics to create more precise and individualized medical treatments. The ability to manipulate genomes at a granular level, coupled with advanced techniques such as CRISPR-Cas9 gene editing and genome synthesis, has provided powerful tools for developing personalized therapies. This review explores the applications of synthetic biology in personalized medicine, focusing on the creation of tailored treatments, gene therapies, synthetic vaccines, and diagnostic systems. We also address the ethical, regulatory, and safety concerns surrounding these technologies, as well as their future potential.

Keywords: Synthetic Biology, Genetic Engineering, Personalized therapies, Synthetic vaccines.

Introduction

Personalized medicine is an evolving approach to healthcare that tailors medical decisions, practices, and treatments to the individual characteristics of each patient (1). Unlike the traditional “one-size-fits-all” model, which assumes a universal treatment plan for all individuals, personalized medicine takes into account a wide array of factors unique to each patient. These include genetic makeup, environmental exposures, lifestyle choices, and

even cultural background, all of which can influence how a patient responds to different therapies (2). By integrating these individual characteristics into the treatment process, personalized medicine aims to provide more effective, precise, and safer healthcare, improving outcomes while minimizing the risk of adverse effects (3).

The emergence of synthetic biology and genomics has significantly advanced the potential of personalized medicine, marking the beginning

COPYRIGHTS

The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article:

N.Ehyaei Rad, "Synthetic Biology in Genomics: Redefining Genetic Engineering and Its Applications in Personalized Medicine", *Advanced Therapies Journal*, vol. 7, no. 22, pp. 61-69, 2025.

of a new era in healthcare. Synthetic biology, which involves the design and construction of new biological parts, devices, and systems, is transforming the way we understand and treat disease (4). By enabling the manipulation of genetic material with unprecedented precision, synthetic biology offers innovative solutions to a range of medical challenges. It provides the tools to design tailored genetic systems that can address specific genetic mutations, which could lead to more effective treatments for genetic disorders. Additionally, synthetic biology has opened new possibilities in the development of personalized vaccines, which can be designed to target an individual's specific immune responses (5). Furthermore, advancements in diagnostic technologies, fueled by the integration of genomics and synthetic biology, promise to offer more accurate and rapid methods for detecting diseases at their earliest stages (6).

The combination of genomics and synthetic biology is particularly transformative in the field of personalized medicine, allowing for highly targeted therapies that are customized to the molecular characteristics of each patient's disease. For example, in oncology, genetic profiling of tumors can identify mutations and alterations specific to an individual's cancer, enabling the development of targeted therapies that attack cancer cells without harming healthy tissue. Similarly, personalized immunotherapies, such as CAR-T cell therapy, are being developed to harness and enhance a patient's immune system to specifically target and destroy cancer cells (7).

Despite the immense potential of personalized medicine, these advancements are not without their challenges. Ethical concerns surrounding privacy, genetic data sharing, and the accessibility of personalized treatments are critical issues that need to be addressed as these technologies continue to evolve (8). Additionally, the complexity of designing and implementing these advanced therapies in clinical settings presents logistical and regulatory hurdles that must be overcome to ensure that patients benefit from these innovations safely and equitably.

This paper explores how synthetic biology is revolutionizing personalized medicine by examining the technological advancements driving this transformation, the therapeutic applications that are already emerging, and the ethical considerations that accompany these groundbreaking developments. By delving into both the promise and the challenges of this new era in medicine, the paper aims to provide a comprehensive overview of how synthetic biology is reshaping the future of personalized healthcare.

Synthetic Biology and Personalized Medicine: A New Paradigm

The Role of Synthetic Biology in Personalized Medicine

Synthetic biology has introduced a transformative paradigm in medicine, often referred to as "programmable biology," where biological systems and genetic material are engineered and reprogrammed to serve specific therapeutic purposes. This capability represents a profound shift in the way diseases are understood and treated, as it enables the creation of highly customized therapies that are tailored to the individual genetic and molecular makeup of each patient. By manipulating biological systems at the genetic level, synthetic biology empowers clinicians and researchers to address the underlying causes of disease rather than merely treating symptoms.

In personalized medicine, the concept of tailoring treatment to an individual's unique genetic profile is becoming increasingly important. Traditional medical approaches often rely on generalized treatments that target broad mechanisms of disease, which may not be equally effective for all patients. In contrast, synthetic biology allows for the precise engineering of genetic circuits, biosensors, and gene-editing technologies to directly address the specific genetic mutations and molecular pathways driving a patient's disease. This results in therapies that are not only more effective but also carry fewer risks of adverse effects, as they can be fine-tuned to target the disease at its molecular source. The ability to design and deploy personalized treatments offers a profound advantage, particularly in fields like oncology, genetic disorders, and immunology, where individual patient responses can vary widely.

As a key enabler of personalized medicine, synthetic biology facilitates the creation of patient-specific therapies that provide more accurate, safer, and potentially curative options. The intersection of synthetic biology with genomics, bioinformatics, and advanced diagnostics is unlocking new avenues for treating diseases that were previously considered intractable or difficult to manage, further advancing the shift toward precision medicine.

Key Technologies Driving Personalized Medicine

Several groundbreaking advancements in synthetic biology are revolutionizing the way personalized medicine is conceptualized and delivered. These technologies allow for the precise manipulation of genetic material, enabling the development of highly personalized treatments that are tailored to the genetic and molecular profiles of individual patients. Key technologies driving this revolution include:

1. CRISPR-Cas9 and Genome Editing

The advent of CRISPR-Cas9 technology has marked a watershed moment in the field of genetics and personalized medicine. CRISPR-Cas9 allows for

precise, targeted editing of genes at specific locations in the genome, offering unprecedented accuracy and flexibility in correcting genetic mutations responsible for various diseases. This tool works by harnessing a naturally occurring bacterial defense mechanism to cut DNA at specific sites, which can then be modified or replaced to correct genetic defects.

For example, CRISPR has shown tremendous promise in treating genetic disorders like sickle cell anemia, where the underlying genetic mutation can be corrected in the patient's cells, offering the potential for a permanent cure. This capability extends to a wide range of diseases caused by single-gene mutations, such as cystic fibrosis and Duchenne muscular dystrophy, where personalized gene therapies could provide patients with individualized, life-changing treatment options. In the realm of cancer, CRISPR technology can be used to modify immune cells, enhancing their ability to target and destroy cancer cells more effectively, offering new prospects for personalized immunotherapies.

2. Gene Synthesis and Custom Pathways

Gene synthesis and the creation of custom metabolic pathways is another powerful tool enabled by synthetic biology. By synthesizing entire genes or creating new biochemical pathways from scratch, scientists can engineer biological systems that perform specific, therapeutic functions. These custom-designed pathways can be used to modify the metabolic processes within a patient's cells, offering potential treatments for a variety of conditions, including metabolic diseases, cancer, and neurodegenerative disorders.

For instance, synthetic biologists can design therapeutic enzymes that replace faulty ones in patients with genetic metabolic disorders, or they can reprogram cells to produce beneficial molecules such as proteins or hormones that the body cannot produce on its own. Additionally, the ability to construct artificial biosynthetic pathways enables the creation of personalized treatments for diseases such as cancer, where novel pathways can be engineered to specifically target cancerous cells, minimizing harm to healthy tissues.

The combination of gene synthesis with advanced techniques in genome editing allows for the construction of personalized therapies that are tailored to the individual biochemical environment of each patient, improving both efficacy and safety.

3. Cellular and Gene Therapy

Gene therapy, driven by synthetic biology, is poised to become a cornerstone of personalized medicine. This approach involves introducing modified genes into a patient's cells to correct genetic defects or to enable the body to produce therapeutic substances.

The rise of gene therapy has been particularly transformative in the treatment of inherited genetic disorders, where traditional methods of treatment were either insufficient or non-existent.

Autologous stem cell therapy, for example, is being employed in personalized cancer treatment. In this method, a patient's stem cells are harvested, genetically modified, and reintroduced into their body to target specific diseases, such as cancer. In the case of personalized cancer immunotherapy, immune cells, such as T cells, are engineered to recognize and attack cancer cells more effectively. The result is a highly personalized treatment that harnesses the body's immune system to fight the disease, offering the potential for more effective and durable responses compared to traditional treatments like chemotherapy or radiation.

Gene therapies are also being developed for rare genetic diseases, such as spinal muscular atrophy (9), where the delivery of a functional copy of a missing or defective gene can dramatically improve patient outcomes. The use of viral vectors or CRISPR-based techniques to deliver gene therapies is rapidly advancing, enabling more targeted and efficient treatments with reduced side effects.

4. Synthetic Biology-Driven Diagnostics

Effective personalized medicine relies not only on precise treatments but also on equally precise diagnostics. The ability to accurately diagnose diseases based on an individual's unique genetic and molecular profile is essential for tailoring therapies that are most likely to be effective. Synthetic biology plays a crucial role in the development of highly sensitive diagnostic tools that can identify specific genetic markers, proteins, or other biomarkers associated with particular diseases (10).

Innovative biosensors, developed using synthetic biology techniques, can detect and measure minute levels of disease markers in a patient's body. These tools have the potential to identify diseases at their earliest stages, enabling early intervention and better outcomes. Additionally, synthetic biology-driven diagnostics can be used to monitor how a patient is responding to personalized therapy, allowing for real-time adjustments to the treatment plan based on the patient's response (11). This level of precision in monitoring and diagnosing disease is a key component of personalized medicine, ensuring that therapies remain tailored and optimized throughout the course of treatment (12).

Moreover, synthetic biology is enabling the development of portable and cost-effective diagnostic platforms, which could make personalized medicine more accessible to patients in low-resource settings. These advances may bring personalized healthcare to a broader population, making it more inclusive and

equitable (13).

These technological advancements in synthetic biology are ushering in a new era of personalized medicine, providing innovative tools to tailor treatments and diagnostics to the individual genetic and molecular profile of each patient. As these technologies continue to evolve, they hold the promise of revolutionizing the way diseases are treated, offering more effective, safer, and customized healthcare solutions that address the unique needs of every patient (14).

Applications of Synthetic Biology in Personalized Medicine

Gene Therapy and Editing

Gene therapy is a cornerstone of personalized medicine, and synthetic biology plays a pivotal role in its development. In traditional gene therapy, genes are introduced into a patient's cells to correct genetic defects or treat diseases (15). Synthetic biology enables the engineering of precise gene-editing tools, such as CRISPR, that can target specific genes and correct mutations with higher efficiency and accuracy. For instance, sickle cell disease is caused by a mutation in the hemoglobin gene (16). Using CRISPR-Cas9, scientists can edit the genome of hematopoietic stem cells, enabling the correction of the mutation in a patient's blood cells. This can potentially cure the patient by restoring normal hemoglobin function (17). Such gene-editing technologies are central to developing individualized treatments for genetic diseases, where the patient's specific genetic defects can be addressed. Another example is cystic fibrosis, which results from mutations in the CFTR gene (18). Synthetic biology techniques, including gene delivery systems, could be used to deliver a healthy version of the CFTR gene to lung cells, providing personalized treatments for affected individuals (19).

Personalized Cancer Therapy

Synthetic biology holds immense promise in the treatment of cancer. Personalized cancer therapies are designed based on the unique genetic makeup of a patient's tumor. Unlike traditional cancer treatments, which are based on general protocols, personalized therapies focus on the specific mutations and molecular markers present in the patient's cancer cells (20).

One approach involves CAR-T (Chimeric Antigen Receptor T-cell) therapy, where a patient's T-cells are genetically engineered to target cancer cells. Synthetic biology tools are used to design the receptors on T-cells that recognize and bind to tumor-specific antigens (21). This allows for a personalized approach, as the therapy is customized to the specific

cancer type and tumor characteristics of each patient. Additionally, synthetic biology is used to engineer microbes that can target and destroy cancer cells (22). For instance, synthetic bacteria can be programmed to recognize cancerous cells and deliver therapeutic payloads, such as toxins or immune-stimulating compounds, directly to the tumor site. This precision medicine approach reduces the risk of damage to healthy tissues, a common side effect of traditional cancer treatments (23).

Personalized Vaccines

Vaccines are typically designed to elicit a broad immune response. However, personalized vaccines are tailored to an individual's genetic profile, enhancing their effectiveness (24). Synthetic biology can be employed to design synthetic vaccines based on the specific viral or bacterial strains that a person is most likely to encounter, taking into account their genetic makeup and immune system response (25).

Personalized cancer vaccines are another area of active research. These vaccines are tailored to target specific mutations or antigens expressed by an individual's cancer cells. Synthetic biology allows for the design of synthetic peptides or genetic materials that can stimulate an immune response against these tumor-specific markers. For instance, a synthetic vaccine could be designed for a patient with melanoma, targeting the specific mutations found in their cancer cells (26).

Personalized Diagnostic Systems

Accurate and early diagnosis is critical for the success of personalized medicine. Synthetic biology enables the development of highly sensitive and specific diagnostic tools, such as biosensors and genetic tests, that can detect disease markers at the molecular level (11). These tools can be tailored to an individual's unique genetic profile, providing more accurate diagnoses and guiding treatment decisions (27). For example, gene expression profiling can be used to identify biomarkers that are associated with specific diseases. These biomarkers can be used to develop diagnostic tests that can detect the presence of disease before symptoms arise, allowing for early intervention and personalized treatment (28, 29).

Synthetic Biology and Microbiome Engineering

The human microbiome—the trillions of microorganisms living in and on our bodies—plays a significant role in health and disease. Synthetic biology offers the potential to engineer the microbiome to benefit personalized medicine (30). By modifying the genetic makeup of microbial communities, researchers can develop personalized treatments that influence the microbiome in ways that improve health outcomes (31).

For example, the microbiome is known to affect drug metabolism, immune responses, and disease susceptibility. Synthetic biology can be used to design engineered microbes that produce therapeutic molecules or regulate the immune system. These engineered microbes could be delivered as probiotics to restore balance to the microbiome in individuals with specific health conditions, such as inflammatory bowel disease or metabolic disorders (32).

Challenges and Ethical Considerations in Personalized Medicine

While the integration of synthetic biology into personalized medicine holds tremendous promise, there are still several significant challenges that need to be addressed (33). These challenges encompass both technical and ethical issues, each of which plays a crucial role in the future development, accessibility, and societal acceptance of these advanced therapies (34). Overcoming these barriers is essential for ensuring that the full potential of personalized medicine can be realized in a safe, ethical, and equitable manner.

Technical Challenges

One of the primary technical hurdles is the complexity of designing and delivering gene therapies effectively. Gene therapies require precise modification of an individual's genetic material, and achieving this with a high degree of accuracy remains a challenging task (35). Technologies like CRISPR-Cas9 have shown remarkable potential in editing genes, but there are still concerns regarding off-target effects, where unintended parts of the genome may be altered, leading to unintended consequences (36). Moreover, ensuring the safe and efficient delivery of gene-editing tools to the right cells in the body is a critical challenge, as current delivery systems, such as viral vectors, can be inefficient and may trigger immune responses. Overcoming these technical limitations is crucial for advancing the field of gene therapy and ensuring its success in clinical applications (37).

Another challenge lies in the scalability and production of personalized therapies. As treatments are tailored to individual patients, the process of developing and manufacturing these therapies becomes highly individualized, which can make it difficult to produce them in large quantities (38). The high degree of customization required for each patient increases the time and cost involved in the development of treatments, raising concerns about the overall feasibility of delivering personalized medicine on a large scale (1).

Safety Concerns

Safety remains one of the most significant concerns

in the use of synthetic biology in personalized medicine. Gene-editing technologies, such as CRISPR, present unique risks, particularly when it comes to editing the human genome (39). Unintended genetic changes or "off-target" effects could have serious health consequences, including the potential to activate cancer-causing genes or disrupt essential cellular functions. Although improvements in gene-editing technologies are reducing the risk of such unintended effects, further research and safeguards are required to ensure the long-term safety of these therapies (40).

Another safety concern is the use of synthetic microorganisms or engineered microbes in therapeutic applications. While genetically engineered bacteria or viruses may be used to deliver drugs or genes to specific areas of the body, there is the risk that these organisms may behave unpredictably, causing harm to the patient or triggering immune reactions (41). Rigorous testing and monitoring protocols must be established to ensure that these engineered organisms are safe and do not pose unforeseen risks (42).

Accessibility and Cost

The high cost of personalized therapies presents another challenge. Many of the cutting-edge treatments made possible by synthetic biology, such as gene therapies, are expensive to develop, produce, and administer (43). These costs are often passed on to patients, making access to personalized medicine a significant issue for many individuals, particularly those in low- and middle-income countries (44). The affordability of these therapies is a major concern, as the potential benefits of personalized treatments may be out of reach for large segments of the global population (45).

In addition to cost, there are also concerns about the availability of specialized infrastructure and expertise required to deliver these therapies. For example, gene therapies often require sophisticated diagnostic tools and facilities capable of monitoring patient responses to treatment (46). The lack of such resources in resource-poor settings could exacerbate existing healthcare disparities, leaving certain populations without access to potentially life-saving treatments.

Ethical Considerations

Alongside the technical and logistical challenges, several ethical issues must be addressed as synthetic biology is integrated into personalized medicine. These ethical concerns are pivotal in guiding the development, regulation, and public acceptance of new treatments (47). Some of the key ethical issues include:

Genetic Privacy and Data Security

The use of genetic data is at the core of personalized medicine, as treatments are increasingly based on an individual's genetic makeup. However, the collection, storage, and sharing of such sensitive information raise significant privacy concerns (48). Genetic data can reveal deeply personal information about an individual's health, ancestry, and predisposition to various diseases, making it a potential target for misuse. Ensuring that individuals' genetic data is protected from unauthorized access, hacking, or exploitation is critical to maintaining trust in personalized medicine (49). Strong data protection laws, as well as secure storage and encryption technologies, are essential to safeguard genetic information (50).

Additionally, there are concerns about how genetic data might be used by third parties, such as insurance companies or employers, which could potentially lead to discrimination based on genetic predispositions. Ethical guidelines and legal frameworks must be established to ensure that individuals' genetic data is used responsibly and for the benefit of patients, without infringing upon their privacy or rights (51).

Equity and Access

One of the most pressing ethical concerns in personalized medicine is ensuring that these advanced therapies are accessible to all, regardless of socioeconomic status or geographic location (52). The high cost of personalized treatments poses a significant barrier to access, and there is the risk that only wealthier individuals or those living in developed countries will benefit from these innovations (53). In a world where healthcare disparities already exist, the advent of personalized medicine could exacerbate inequities if not carefully managed.

There is a critical need for policies that ensure equal access to personalized treatments across all populations. This includes addressing the affordability of therapies, as well as improving healthcare infrastructure in underserved areas (54). Efforts must be made to ensure that personalized medicine is not a privilege for the few but a benefit for all, with equitable distribution of these therapies across diverse social, economic, and geographical groups (55).

Regulation of Gene Editing

The ability to edit the human genome using technologies like CRISPR-Cas9 presents both immense opportunities and significant risks. While gene editing holds the potential to cure genetic diseases and improve patient outcomes, it also raises concerns about unintended consequences and the ethical implications of altering the human germline (the genetic material passed on to future generations) (56). The modification of the human genome could

have long-lasting effects, not only on the individual receiving treatment but also on their descendants (9).

As gene-editing technologies continue to evolve, regulatory frameworks must be established to ensure that they are used responsibly. These regulations must include guidelines for conducting research, clinical trials, and therapeutic applications, as well as oversight mechanisms to monitor the long-term effects of gene editing. International consensus on the ethical boundaries of gene editing will be crucial in preventing misuse or overly permissive policies that could lead to harmful genetic modifications (57).

Designer Babies

One of the most controversial ethical concerns related to gene editing is the potential for creating "designer babies." This term refers to the possibility of editing human embryos to select desirable traits, such as intelligence, physical appearance, or disease resistance. While the technology to edit embryos exists, the ethical questions surrounding this practice are profound (58). Many worry about the social and moral implications of allowing parents or clinicians to decide on genetic traits for their children, potentially leading to a form of genetic elitism or discrimination (59). The idea of creating "designer babies" raises concerns about the ethics of genetic enhancement, as well as the potential for societal pressures to influence genetic choices.

Conclusion

Synthetic biology is transforming personalized medicine, enabling highly targeted treatments tailored to individual genetic, molecular, and environmental factors. Technologies like CRISPR-Cas9 and gene synthesis offer the potential for more effective therapies with fewer side effects, revolutionizing the treatment of genetic disorders and cancers. However, challenges such as technical complexities, safety concerns, high costs, and ethical issues around genetic privacy, access, and enhancement remain. To fully realize its potential, ongoing research, regulatory frameworks, and a commitment to equity are essential. With these efforts, personalized medicine can become widely accessible, improving patient outcomes and advancing global health.

Authors' Contribution

The authors read and confirmed the final manuscript.

Funding

Not applicable.

Availability of data and materials

All data are obtainable after an appeal from the corresponding author.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

References

- 1.Stefanicka-Wojtas D, Kurpas D. Personalised Medicine-Implementation to the Healthcare System in Europe (Focus Group Discussions). *Journal of personalized medicine*. 2023;13(3).
- 2.Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics*. 2024;16(3).
- 3.Alzeer JJJoPH, Emergency. Integrating medicine with lifestyle for personalized and holistic healthcare. 2023. 2023;7.
- 4.David F, Davis AM, Gossing M, Hayes MA, Romero E, Scott LH, et al. A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities. *SLAS Discovery*. 2021;26(5):581-603.
- 5.Hussen BM, Najmadden ZB, Abdullah SR, Rasul MF, Mustafa SA, Ghafouri-Fard S, et al. CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders. *Cell Communication and Signaling*. 2024;22(1):329.
- 6.Shieh JTC. Genomic technologies to improve variation identification in undiagnosed diseases. *Pediatrics & Neonatology*. 2023;64:S18-S21.
- 7.Singh D, Dhiman VK, Pandey M, Dhiman VK, Sharma A, Pandey H, et al. Personalized medicine: An alternative for Cancer Treatment. *Cancer Treatment and Research Communications*. 2024:100860.
- 8.Ghebrehiwet I, Zaki N, Damseh R, Mohamad MS. Revolutionizing personalized medicine with generative AI: a systematic review. *Artificial Intelligence Review*. 2024;57(5):128.
- 9.Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. *Molecular Cancer*. 2024;23(1):9.
- 10.Strianese O, Rizzo F, Ciccarelli M, Galasso G, D'Agostino Y, Salvati A, et al. Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease. *Genes*. 2020;11(7).
- 11.Wang C, Zeng H-S, Liu K-X, Lin Y-N, Yang H, Xie X-Y, et al. Biosensor-based therapy powered by synthetic biology. *Smart Materials in Medicine*. 2023;4:212-24.
- 12.Puccetti M, Pariano M, Schoubben A, Giovagnoli S, Ricci M. Biologics, theranostics, and personalized medicine in drug delivery systems. *Pharmacological Research*. 2024;201:107086.
- 13.Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics* [Internet]. 2024; 16(3).
- 14.Abbaoui W, Retal S, El Bhiri B, Kharmoum N, Ziti S. Towards revolutionizing precision healthcare: A systematic literature review of artificial intelligence methods in precision medicine. *Informatics in Medicine Unlocked*. 2024;46:101475.
15. Sharma D, Arora S, Singh J, Layek B. A review of the tortuous path of nonviral gene delivery and recent progress. *International Journal of Biological Macromolecules*. 2021;183:2055-73.
- 16.Kolanu ND. CRISPR-Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications. *Global medical genetics*. 2024;11(1):113-22.
- 17.Gabr H, El Ghamrawy MK, Almaeen AH, Abdelhafiz AS, Hassan AOS, El Sissy MH. CRISPR-mediated gene modification of hematopoietic stem cells with beta-thalassemia IVS-1-110 mutation. *Stem Cell Research & Therapy*. 2020;11(1):390.
- 18.Wang G. Genome Editing for Cystic Fibrosis. *Cells*. 2023;12(12).
- 19.Sui H, Xu X, Su Y, Gong Z, Yao M, Liu X, et al. Gene therapy for cystic fibrosis: Challenges and prospects. *Frontiers in pharmacology*. 2022;13:1015926.
- 20.Tsimberidou AM, Fountzilias E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer treatment reviews*. 2020;86:102019.
- 21.R.S A, R M, Sastri KT, G.S M, A.R A, V B. Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies. *Life Sciences*. 2024;358:123186.
- 22.Krzyszczak P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, et al. The growing role of precision and personalized medicine for cancer treatment. *Technology*. 2018;6(3-4):79-100.
- 23.Sieow BF-L, Wun KS, Yong WP, Hwang IY, Chang MW. Tweak to Treat: Reprogramming Bacteria for Cancer Treatment. *Trends in Cancer*. 2021;7(5):447-64.
- 24.Montin D, Santilli V, Beni A, Costagliola G, Martire B, Mastrototaro MF, et al. Towards personalized vaccines. *Frontiers in immunology*. 2024;15:1436108.

25. Charlton Hume HK, Vidigal J, Carrondo MJT, Middelberg APJ, Roldão A, Lua LHL. Synthetic biology for bioengineering virus-like particle vaccines. *Biotechnology and bioengineering*. 2019;116(4):919-35.
26. Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. *Signal transduction and targeted therapy*. 2023;8(1):450.
27. Mathur S, Sutton J. Personalized medicine could transform healthcare. *Biomedical reports*. 2017;7(1):3-5.
28. Wang RC, Wang Z. Precision Medicine: Disease Subtyping and Tailored Treatment. *Cancers*. 2023;15(15).
29. Hassan M, Awan FM, Naz A, deAndrés-Galiana EJ, Alvarez O, Cernea A, et al. Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. *International journal of molecular sciences*. 2022;23(9).
30. Tomasulo A, Simionati B, Facchin S. Microbiome One Health model for a healthy ecosystem. *Science in One Health*. 2024;3:100065.
31. Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. *Chemical reviews*. 2023;123(1):31-72.
32. Dou J, Bennett MR. Synthetic Biology and the Gut Microbiome. *Biotechnology journal*. 2018;13(5):e1700159.
33. Huo D, Wang X. A new era in healthcare: The integration of artificial intelligence and microbial. *Medicine in Novel Technology and Devices*. 2024;23:100319.
34. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. *Fertility and sterility*. 2018;109(6):952-63.
35. Aljabali AAA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery. *Journal of Drug Delivery Science and Technology*. 2024;92:105338.
36. Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR/Cas9 gene editing. *Frontiers in bioengineering and biotechnology*. 2023;11:1143157.
37. Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. *Journal of Controlled Release*. 2022;342:345-61.
38. Amekyeh H, Tarlochan F, Billa N. Practicality of 3D Printed Personalized Medicines in Therapeutics. *Frontiers in pharmacology*. 2021;12:646836.
39. Vasudevan SS, Kandrikar TY, Sayyed AA, Sridhar S, Prasad A, Khandelwal S, et al. Chapter 13 - Personalized vaccines, novel vaccination technologies, and future prospects. In: Chavda VP, Vora LK, Apostolopoulos V, editors. *Advanced Vaccination Technologies for Infectious and Chronic Diseases*: Academic Press; 2024. p. 225-42.
40. Merlin JPJ, Abrahamse H. Optimizing CRISPR/Cas9 precision: Mitigating off-target effects for safe integration with photodynamic and stem cell therapies in cancer treatment. *Biomedicine & Pharmacotherapy*. 2024;180:117516.
41. Jin K, Huang Y, Che H, Wu Y. Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology. *Microbial biotechnology*. 2025;18(1):e70080.
42. Prakash D, Verma S, Bhatia R, Tiwary BN. Risks and Precautions of Genetically Modified Organisms. 2011;2011(1):369573.
43. Carr DR, Bradshaw SE. Gene therapies: the challenge of super-high-cost treatments and how to pay for them. *Regenerative medicine*. 2016;11(4):381-93.
44. Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. *Molecular & Cellular Proteomics*. 2024;23(3):100737.
45. Chen W, Wang Y, Zemlyanska Y, Butani D, Wong NCB, Virabhak S, et al. Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges. *Value in Health*. 2023;26(9):1425-34.
46. Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B, et al. Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2018;26(12):2717-26.
47. Brothers KB, Rothstein MA. Ethical, legal and social implications of incorporating personalized medicine into healthcare. *Personalized medicine*. 2015;12(1):43-51.
48. Bonomi L, Huang Y, Ohno-Machado L. Privacy challenges and research opportunities for genomic data sharing. *Nature genetics*. 2020;52(7):646-54.
49. Schumacher GJ, Sawaya S, Nelson D, Hansen AJ. Genetic Information Insecurity as State of the Art. *Frontiers in bioengineering and biotechnology*. 2020;8:591980.
50. Sariyar M, Suhr S, Schlünder I. How Sensitive Is Genetic Data? Biopreservation and biobanking. 2017;15(6):494-501.
51. Niemiec E, Howard HC. Ethical issues in consumer genome sequencing: Use of consumers' samples and data. *Applied & Translational Genomics*. 2016;8:23-30.
52. Cinti C, Trivella MG, Joulie M, Ayoub H,

- Frenzel M. The Roadmap toward Personalized Medicine: Challenges and Opportunities. *Journal of personalized medicine* [Internet]. 2024; 14(6).
53. Masucci M, Karlsson C, Blomqvist L, Ernberg I. Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine. *Journal of personalized medicine* [Internet]. 2024; 14(6).
54. Jindal M, Chaiyachati KH, Fung V, Manson SM, Mortensen K. Eliminating health care inequities through strengthening access to care. *Health services research*. 2023;58 Suppl 3(Suppl 3):300-10.
55. Bantham A, Taverno Ross SE, Sebastião E, Hall G. Overcoming barriers to physical activity in underserved populations. *Progress in Cardiovascular Diseases*. 2021;64:64-71.
56. Ansori AN, Antonius Y, Susilo RJ, Hayaza S, Kharisma VD, Parikesit AA, et al. Application of CRISPR-Cas9 genome editing technology in various fields: A review. *Narra J*. 2023;3(2):e184.
57. Conley JM, Davis AM, Henderson GE, Juengst ET, Meagher KM, Walker RL, et al. A New Governance Approach to Regulating Human Genome Editing. *North Carolina journal of law & technology*. 2020;22(2):107-41.
58. So D. From goodness to good looks: Changing images of human germline genetic modification. *Bioethics*. 2022;36(5):556-68.
59. Arnos KS. Ethical and social implications of genetic testing for communication disorders. *Journal of communication disorders*. 2008;41(5):444-57.